IgAN
European Renal Association (ERA) 2025
Vienna, Austria
June 4-7, 2025
Posters
-
ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN Lafayette R, et al.
Lafayette R, et al.
-
ORIGIN 3 Study Design: A Global, Randomized, Controlled, Phase 3 Study of Atacicept in IgA Nephropathy (IgAN)
Lafayette R, et al.
Focused Oral Presentation
-
ORIGIN 2b: Changes in Gd-IgA1 and eGFR 26 Weeks After Discontinuation of Atacicept Treatment in IgA Nephropathy
Barratt J, et al.
Industry-Sponsored Symposium
-
Targeting the Source of IgA Nephropathy: Focus on B-Cell Modulation
Presented by: Dr. Dana Rizk, Dr. Shikha Wadhwani, and Dr. Richard Lafayette